Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Axitinib in neoadjuvant clear cell renal cell carcinoma
NCT04118855Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in clear cell renal cell carcinoma (ccRCC), sponsored by Renji Hospital. Primary endpoint: Objective Tumor Response Rate at 3 months. Started Mar 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04118855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118855.